Daily News Podcast

Brain damage, slight benefit seen in epinephrine cardiac arrest


 

Epinephrine provided a slight 30-day survival benefit, but those patients experienced more severe brain damage. Also today, nerve growth factor inhibitor shows phase-3 efficacy in osteoarthritis, National Academies issues a 5-step plan to address infections linked to opioid use disorder, and there may be beneficial class effects of SGLT2 inhibitors, including dapagliflozin. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

CDC releases website for ME/CFS information
MDedge Internal Medicine
AHRQ National Guideline Clearinghouse shutting down
MDedge Internal Medicine
Less documentation highlights new Medicare fee proposal
MDedge Internal Medicine
Too many antibiotics prescribed in urgent care
MDedge Internal Medicine
Better ICU staff communication with family may improve end-of-life choices
MDedge Internal Medicine
Managing HIV with diabetes
MDedge Internal Medicine
Nearly one-quarter of presurgery patients already using opioids
MDedge Internal Medicine
Telemedicine payment expansion?
MDedge Internal Medicine
Epinephrine for cardiac arrest: Better survival, more brain damage
MDedge Internal Medicine
Bundle pay plan didn’t save money
MDedge Internal Medicine